

John B Porter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8617706/publications.pdf>

Version: 2024-02-01

199
papers

11,609
citations

19608

61
h-index

32761

100
g-index

200
all docs

200
docs citations

200
times ranked

7289
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. <i>British Journal of Haematology</i> , 2022, 196, 336-350.	1.2	11
2	Response to Cabantchik and Hershko commentary "Plasma nontransferrin bound iron" nontransferrin bound iron revisited: Implications for systemic iron overload and in iv iron supplementation. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	0
3	Betibeglogene Autotemcel Gene Therapy for Non- β^0/β^0 Genotype β^2 -Thalassemia. <i>New England Journal of Medicine</i> , 2022, 386, 415-427.	13.9	91
4	Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro. <i>Blood Advances</i> , 2022, 6, 13-27.	2.5	2
5	An open-label, multicenter, efficacy, and safety study of deferasirox in iron-overloaded patients with non-transfusion-dependent thalassemia (THETIS): 5-year results. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	2
6	Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β^2 -thalassemia: current evidence and future clinical development. <i>Expert Review of Hematology</i> , 2021, 14, 633-644.	1.0	13
7	Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways. <i>Haematologica</i> , 2021, 106, 2885-2896.	1.7	28
8	Anti-Platelet Aggregation and Anti-Cyclooxygenase Activities for a Range of Coffee Extracts (Coffea) Tj ETQq0 0 0 rBT /Overlock 10 Tf 5	1.7	15
9	Consumption of a green tea extract "curcumin drink decreases blood urea nitrogen and redox iron in β^2 -thalassemia patients. <i>Food and Function</i> , 2020, 11, 932-943.	2.1	26
10	A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β^2 -Thalassemia. <i>New England Journal of Medicine</i> , 2020, 382, 1219-1231.	13.9	177
11	Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 189, 635-639.	1.2	45
12	Decrement in Cellular Iron and Reactive Oxygen Species, and Improvement of Insulin Secretion in a Pancreatic Cell Line Using Green Tea Extract. <i>Pancreas</i> , 2019, 48, 636-643.	0.5	21
13	Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis. <i>American Journal of Hematology</i> , 2019, 94, E96-E99.	2.0	5
14	Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study. <i>American Journal of Hematology</i> , 2019, 94, E15-E17.	2.0	2
15	Interaction of Transfusion and Iron Chelation in Thalassemias. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 247-259.	0.9	12
16	A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?. <i>Blood Reviews</i> , 2018, 32, 300-311.	2.8	95
17	Psychological Factors Associated with Episodic Chelation Adherence in Thalassemia. <i>Hemoglobin</i> , 2018, 42, 30-36.	0.4	9
18	Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 216.	1.0	15

#	ARTICLE	IF	CITATIONS
19	Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy. Hematology American Society of Hematology Education Program, 2018, 2018, 361-370.	0.9	25
20	Effect of Ljpc-401 (synthetic human hepcidin) on Iron Parameters in Healthy Adults. Blood, 2018, 132, 2336-2336.	0.6	5
21	Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. British Journal of Haematology, 2017, 176, 179-191.	1.2	76
22	New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study. American Journal of Hematology, 2017, 92, 420-428.	2.0	66
23	Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. British Journal of Haematology, 2017, 176, 288-299.	1.2	43
24	Non-invasive MRI biomarkers for the early assessment of iron overload in a humanized mouse model of β^0 -thalassemia. Scientific Reports, 2017, 7, 43439.	1.6	15
25	Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood, 2017, 130, 1923-1933.	0.6	98
26	Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin. Haematologica, 2017, 102, 1640-1649.	1.7	18
27	One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatric Blood and Cancer, 2017, 64, 188-196.	0.8	24
28	Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia. European Journal of Haematology, 2017, 98, 280-288.	1.1	29
29	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy, 2016, Volume 10, 4073-4078.	2.0	15
30	Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. Haematologica, 2016, 101, 38-45.	1.7	74
31	Red blood cell-derived microparticles: An overview. Blood Cells, Molecules, and Diseases, 2016, 59, 134-139.	0.6	58
32	Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World. Circulation, 2016, 134, 432-434.	1.6	23
33	Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay. Translational Research, 2016, 177, 19-30.e5.	2.2	17
34	Detection of metallic cobalt and chromium liver deposition following failed hip replacement using T2* and R2 magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 29.	1.6	24
35	Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. European Journal of Haematology, 2016, 96, 19-26.	1.1	27
36	Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells, Molecules, and Diseases, 2016, 57, 23-29.	0.6	24

#	ARTICLE	IF	CITATIONS
37	Symptomatic Erythrocytosis Due to Homozygosity for Hb Luton [<i>HBA2</i> : c.269A>T (or <i>HBA1</i>)] and β -Thalassemia: A Clinical Update. <i>Hemoglobin</i> , 2016, 40, 127-129.	0.4	0
38	Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. <i>European Journal of Internal Medicine</i> , 2016, 28, 91-96.	1.0	14
39	New insights into transfusion-related iron toxicity: Implications for the oncologist. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 261-271.	2.0	46
40	Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 19, 36.	1.6	14
41	Effect of automated red cell exchanges on oxygen saturation on-air, blood parameters and length of hospitalization in sickle cell disease patients with acute chest syndrome. <i>Nigerian Medical Journal</i> , 2016, 57, 190.	0.6	7
42	Hepcidin is suppressed by erythropoiesis in hemoglobin E β^2 -thalassemia and β^2 -thalassemia trait. <i>Blood</i> , 2015, 125, 873-880.	0.6	56
43	Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization. <i>British Journal of Haematology</i> , 2015, 170, 874-883.	1.2	29
44	Noncontrast myocardial T_1 mapping using cardiovascular magnetic resonance for iron overload. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1505-1511.	1.9	139
45	Sustained improvements in myocardial T_2^* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. <i>American Journal of Hematology</i> , 2015, 90, 91-96.	2.0	43
46	Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. <i>European Journal of Haematology</i> , 2015, 95, 244-253.	1.1	61
47	Myocardial iron quantification using T_2^* and native T_1 mapping - a 250 patient study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, P312.	1.6	2
48	Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. <i>Blood</i> , 2015, 125, 3868-3877.	0.6	67
49	Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. <i>British Journal of Haematology</i> , 2015, 168, 284-290.	1.2	50
50	Dysregulated arginine metabolism and cardiopulmonary dysfunction in patients with thalassaemia. <i>British Journal of Haematology</i> , 2015, 169, 887-898.	1.2	22
51	Residual Erythropoiesis Protects Against Cardiac Iron Loading in Transfusion Dependent Thalassaemia (TDT) By Lowering Labile Plasma Iron (LPI) through Transient Apotransferrin Generation. <i>Blood</i> , 2015, 126, 539-539.	0.6	5
52	Mechanisms of plasma transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients. <i>British Journal of Haematology</i> , 2014, 167, 692-696.	1.2	54
53	A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry. <i>Biochemical Journal</i> , 2014, 463, 351-362.	1.7	27
54	Effect of a novel oral active iron chelator: 1-(N-acetyl-6-aminoethyl)-3-hydroxy-2-methylpyridin-4-one (CM1) in iron-overloaded and non-overloaded mice. <i>Asian Pacific Journal of Tropical Medicine</i> , 2014, 7, S155-S161.	0.4	9

#	ARTICLE	IF	CITATIONS
55	High index of suspicion for early diagnosis of alendronate-induced stage zero osteonecrosis of jaw in thalassaemia major. <i>British Journal of Haematology</i> , 2014, 166, 292-294.	1.2	11
56	Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2014, 16, 40.	1.6	143
57	Iron in Haemoglobinopathies and Rare Anaemias. <i>Thalassemia Reports</i> , 2014, 4, 4859.	0.1	2
58	Trauma Induced Inflammation, Sepsis and Ageing. <i>Ageing International</i> , 2014, 39, 243-258.	0.6	0
59	A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β^2 -thalassaemia major (CORDELIA). <i>Blood</i> , 2014, 123, 1447-1454.	0.6	97
60	Iron chelation therapy for non-transfusion-dependent thalassaemia (NTDT): A status quo. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 52, 88-90.	0.6	8
61	Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassaemia: the safety profile of deferasirox. <i>European Journal of Haematology</i> , 2014, 92, 521-526.	1.1	17
62	The Pathophysiology of Transfusional Iron Overload. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 683-701.	0.9	91
63	Calibration of myocardial T2 and T1 against iron concentration. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2014, 16, 62.	1.6	36
64	Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassaemia (NTDT) patients: 1-year extension results from the THALASSA study. <i>Annals of Hematology</i> , 2013, 92, 1485-1493.	0.8	64
65	Treatment of heart failure in adults with thalassaemia major: response in patients randomised to deferoxamine with or without deferiprone. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, 38.	1.6	47
66	On myocardial siderosis and left ventricular dysfunction in hemochromatosis. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, 24.	1.6	32
67	Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassaemia patients. <i>American Journal of Hematology</i> , 2013, 88, 503-506.	2.0	16
68	Combined chelation therapy with deferasirox and deferoxamine in thalassaemia. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 50, 99-104.	0.6	69
69	Increased leucocyte apoptosis in transfused β^2 -thalassaemia patients. <i>British Journal of Haematology</i> , 2013, 160, 399-403.	1.2	7
70	Cross-Talk between Available Guidelines for the Management of Patients with Beta-Thalassaemia Major. <i>Acta Haematologica</i> , 2013, 130, 64-73.	0.7	49
71	Cardiovascular Function and Treatment in β^2 -Thalassaemia Major. <i>Circulation</i> , 2013, 128, 281-308.	1.6	301
72	Consequences and management of iron overload in sickle cell disease. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 447-456.	0.9	122

#	ARTICLE	IF	CITATIONS
73	Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. <i>Haematologica</i> , 2013, 98, 1045-1048.	1.7	49
74	Sildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension. <i>Haematologica</i> , 2013, 98, 1359-1367.	1.7	40
75	Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years. <i>Blood</i> , 2013, 122, 1016-1016.	0.6	3
76	Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. <i>Blood Transfusion</i> , 2013, 11, 108-22.	0.3	17
77	Secondary Erythrocytosis Due to Compound Homozygosity, but not Compound Heterozygosity, for Hb Luton and β -Thalassemia: A Family Study. <i>Hemoglobin</i> , 2012, 36, 7-17.	0.4	2
78	Sudden exertional death in sickle cell trait: Figure 1. <i>British Journal of Sports Medicine</i> , 2012, 46, 312-314.	3.1	42
79	Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β -thalassemia major. <i>Haematologica</i> , 2012, 97, 842-848.	1.7	122
80	Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β -Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial. <i>Anemia</i> , 2012, 2012, 1-10.	0.5	52
81	Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. <i>Blood</i> , 2012, 119, 2746-2753.	0.6	78
82	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. <i>Blood</i> , 2012, 119, 3263-3268.	0.6	48
83	Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. <i>Blood</i> , 2012, 120, 970-977.	0.6	115
84	Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in β -thalassaemia presenting with osteopeniaâ€œosteoporosis syndrome. <i>British Journal of Haematology</i> , 2012, 159, 462-471.	1.2	21
85	Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. <i>Haematologica</i> , 2012, 97, 835-841.	1.7	17
86	Hemoglobinopathies in Pregnancy. , 2012, , 197-217.		1
87	Clinical Use of Iron Chelators. , 2012, , 591-627.		3
88	Transfusion and Chelation Practices in Sickle Cell Disease: A Regional Perspective. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 124-133.	0.3	20
89	Improvement in Liver Pathology of Patients With β -Thalassemia Treated With Deferasirox for at Least 3 Years. <i>Gastroenterology</i> , 2011, 141, 1202-1211.e3.	0.6	73
90	Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials. <i>Blood Cells, Molecules, and Diseases</i> , 2011, 47, 166-175.	0.6	50

#	ARTICLE	IF	CITATIONS
91	Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. <i>Blood</i> , 2011, 118, 3794-3802.	0.6	55
92	A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. <i>Haematologica</i> , 2011, 96, 521-525.	1.7	37
93	Long-term safety and efficacy of deferasirox (Exjade [®]) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. <i>British Journal of Haematology</i> , 2011, 154, 387-397.	1.2	67
94	Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. <i>European Journal of Haematology</i> , 2011, 87, 338-348.	1.1	28
95	The challenges of adherence and persistence with iron chelation therapy. <i>International Journal of Hematology</i> , 2011, 94, 453-460.	0.7	49
96	Iron chelation adherence to deferoxamine and deferasirox in thalassemia. <i>American Journal of Hematology</i> , 2011, 86, 433-436.	2.0	63
97	On T2* Magnetic Resonance and Cardiac Iron. <i>Circulation</i> , 2011, 123, 1519-1528.	1.6	381
98	Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. <i>Blood</i> , 2011, 118, 884-893.	0.6	181
99	Hepcidin and iron species distribution inside the first-trimester human gestational sac. <i>Molecular Human Reproduction</i> , 2011, 17, 227-232.	1.3	38
100	Continued improvement in myocardial T2* over two years of deferasirox therapy in $\hat{\alpha}$ -thalassemia major patients with cardiac iron overload. <i>Haematologica</i> , 2011, 96, 48-54.	1.7	70
101	Efficacy of deferasirox in reducing and preventing cardiac iron overload in $\hat{\alpha}$ -thalassemia. <i>Blood</i> , 2010, 115, 2364-2371.	0.6	168
102	Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. <i>Blood</i> , 2010, 116, 2448-2454.	0.6	63
103	Symptoms of depression and anxiety in patients with thalassemia: Prevalence and correlates in the thalassemia longitudinal cohort. <i>American Journal of Hematology</i> , 2010, 85, 802-805.	2.0	42
104	Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2010, 12, 24.	1.6	15
105	Deferasirox—current knowledge and future challenges. <i>Annals of the New York Academy of Sciences</i> , 2010, 1202, 87-93.	1.8	11
106	Superior Vena Cava Occlusion by Cardiovascular Magnetic Resonance. <i>Circulation</i> , 2010, 122, 853-853.	1.6	1
107	Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. <i>Haematologica</i> , 2010, 95, 557-566.	1.7	260
108	Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. <i>Translational Research</i> , 2010, 156, 55-67.	2.2	59

#	ARTICLE	IF	CITATIONS
109	Pharmacokinetics, Metabolism, and Disposition of Deferasirox in $\hat{\nu}^2$ -Thalassemic Patients with Transfusion-Dependent Iron Overload Who Are at Pharmacokinetic Steady State. <i>Drug Metabolism and Disposition</i> , 2010, 38, 808-816.	1.7	72
110	Relation of myocardial T2* to right ventricular function in thalassaemia major. <i>European Heart Journal</i> , 2010, 31, 1648-1654.	1.0	35
111	Which Psychosocial Factors are Related to Chelation Adherence in Thalassemia? A Systematic Review. <i>Hemoglobin</i> , 2010, 34, 305-321.	0.4	20
112	Iron Overload in Thalassemia and Related Conditions: Therapeutic Goals and Assessment of Response to Chelation Therapies. <i>Hematology/Oncology Clinics of North America</i> , 2010, 24, 1109-1130.	0.9	48
113	A Decade Follow-up of a Thalassemia Major (TM) Cohort Monitored by Cardiac Magnetic Resonance Imaging (CMR): Significant Reduction In Patients with Cardiac Iron and In Total Mortality. <i>Blood</i> , 2010, 116, 1011-1011.	0.6	12
114	Deferiprone Is Associated with Lower Serum Ferritin (SF) Relative to Liver Iron Concentration (LIC) Than Deferoxamine and Deferasirox- Implications for Clinical Practice. <i>Blood</i> , 2010, 116, 4246-4246.	0.6	9
115	Transfusion and Iron Chelation Therapy in Thalassemia and Sickle Cell Disease. , 2009, , 689-744.		2
116	Pathophysiology of Transfusional Iron Overload: Contrasting Patterns in Thalassemia Major and Sickle Cell Disease. <i>Hemoglobin</i> , 2009, 33, S37-S45.	0.4	62
117	Blood Transfusion: Quality and Safety Issues in Thalassemia, Basic Requirements and New Trends. <i>Hemoglobin</i> , 2009, 33, S28-S36.	0.4	8
118	Introduction. <i>Blood Reviews</i> , 2009, 23, S1.	2.8	2
119	Optimizing iron chelation strategies in $\hat{\nu}^2$ -thalassaemia major. <i>Blood Reviews</i> , 2009, 23, S3-S7.	2.8	59
120	Efficacy and safety of deferasirox doses of $\geq 30 \text{ mg/kg per d}$ in patients with transfusionâ€dependent anaemia and iron overload. <i>British Journal of Haematology</i> , 2009, 147, 752-759.	1.2	101
121	Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2009, 11, .	1.6	11
122	Calibration of myocardial iron concentration against T2-star Cardiovascular Magnetic Resonance. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2009, 11, .	1.6	7
123	Deferasirox: An Update. <i>Hemoglobin</i> , 2009, 33, S70-S75.	0.4	9
124	Efficacy and Safety of Deferasirox (Exjade [®]) in $\hat{\nu}^2$ -Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study.. <i>Blood</i> , 2009, 114, 4062-4062.	0.6	4
125	Efficacy and Safety of Deferasirox (Exjade [®]) in Patients with $\hat{\nu}^2$ -Thalassemia Major Treated for up to 5 Years.. <i>Blood</i> , 2009, 114, 4063-4063.	0.6	5
126	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. <i>European Journal of Haematology</i> , 2008, 80, 168-176.	1.1	210

#	ARTICLE	IF	CITATIONS
127	Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. <i>Transfusion</i> , 2008, 48, 1971-1980.	0.8	28
128	Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. <i>British Journal of Haematology</i> , 2008, 142, 126-135.	1.2	142
129	Inflammation and oxidant-stress in $\hat{\alpha}$ -thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis C1CL670A0107 trial. <i>Haematologica</i> , 2008, 93, 817-825.	1.7	67
130	Patient-Reported Outcomes of Deferasirox (Exjade $\hat{\alpha}$ [®] , ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis. <i>Acta Haematologica</i> , 2008, 119, 133-141.	0.7	56
131	Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes GJ, <i>Hemoglobin</i> 2008; 32(1 $\hat{\alpha}$ ²):1 $\hat{\alpha}$ ¹⁵]. <i>Hemoglobin</i> , 2008, 32, 601-607.	0.4	8
132	Effect of transfusional iron intake on response to chelation therapy in $\hat{\beta}^2$ -thalassemia major. <i>Blood</i> , 2008, 111, 583-587.	0.6	161
133	Safety and efficacy of pegylated interferon $\hat{\alpha}$ -2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. <i>Haematologica</i> , 2008, 93, 1247-1251.	1.7	47
134	Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox. <i>Blood</i> , 2008, 112, 116-116.	0.6	13
135	Disease Specific Modulation of Serum Hpcidin: Impact of GDF-15 and Iron Metabolism Markers in Thalassemia Major, Thalassemia Intermedia and Sickle Cell Disease: A Univariate and Multivariate Analysis.. <i>Blood</i> , 2008, 112, 3850-3850.	0.6	2
136	Efficacy and Safety of Deferasirox (Exjade $\hat{\alpha}$ [®]) in Reducing Cardiac Iron in Patients with $\hat{\beta}^2$ -Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial. <i>Blood</i> , 2008, 112, 3873-3873.	0.6	12
137	Efficacy and Safety of Deferasirox (Exjade $\hat{\alpha}$ [®]) in Preventing Cardiac Iron Overload in $\hat{\beta}^2$ -Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial. <i>Blood</i> , 2008, 112, 3874-3874.	0.6	9
138	Effect of Deferasirox (Exjade $\hat{\alpha}$ [®]) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial. <i>Blood</i> , 2008, 112, 3881-3881.	0.6	14
139	Efficacy and Safety of Deferasirox (Exjade $\hat{\alpha}$ [®]) with up to 4.5 Years of Treatment in Patients with Thalassemia Major: A Pooled Analysis. <i>Blood</i> , 2008, 112, 5411-5411.	0.6	9
140	Safety of Deferasirox (Exjade $\hat{\alpha}$ [®]) in Patients with Transfusion-Dependent Anemias and Iron Overload Who Achieve Serum Ferritin Levels $\hat{\leq}$ 1000 Ng/ML during Long-Term Treatment. <i>Blood</i> , 2008, 112, 5423-5423.	0.6	6
141	The Effects of 24 Hour Continuous Deferoxamine Intensification on Serum Creatinine.. <i>Blood</i> , 2008, 112, 1851-1851.	0.6	0
142	Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with $\hat{\beta}^2$ -thalassemia. <i>Clinical Therapeutics</i> , 2007, 29, 909-917.	1.1	123
143	Evaluation of Iron Levels to Avoid the Clinical Sequelae of Iron Overload. <i>Seminars in Hematology</i> , 2007, 44, S2-S6.	1.8	4
144	Clinical Evaluation of Deferasirox (Exjade $\hat{\alpha}$ [®] , ICL670). <i>Seminars in Hematology</i> , 2007, 44, S16-S20.	1.8	5

#	ARTICLE	IF	CITATIONS
145	Concepts and goals in the management of transfusional iron overload. American Journal of Hematology, 2007, 82, 1136-1139.	2.0	86
146	Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. Journal of Magnetic Resonance Imaging, 2007, 25, 1147-1151.	1.9	81
147	Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy. Journal of Magnetic Resonance Imaging, 2007, 26, 564-568.	1.9	52
148	A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 2007, 136, 501-508.	1.2	255
149	Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. Journal of Biological Inorganic Chemistry, 2007, 13, 57-74.	1.1	134
150	Impact of Dose Adjustments on Serum Ferritin (SF) Levels during Long-Term Treatment with Once-Daily, Oral Deferasirox (Exjade®; ICL670).. Blood, 2007, 110, 2778-2778.	0.6	3
151	Evaluation of Deferasirox (Exjade®; ICL670) Therapy in Patients with Transfusional Iron Overload Who Achieve Serum Ferritin (SF) ≤ 1000 ng/mL in Long-Term Studies.. Blood, 2007, 110, 3795-3795.	0.6	6
152	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107, 3455-3462.	0.6	636
153	Oxidative stress and inflammation in iron-overloaded patients with β -thalassaemia or sickle cell disease. British Journal of Haematology, 2006, 135, 254-263.	1.2	260
154	MRI Evidence of Cardiac Iron Accumulation in Myelodysplasia and Unusual Anaemias.. Blood, 2006, 108, 1553-1553.	0.6	9
155	Deferasirox: An effective once-daily orally active iron chelator. Drugs of Today, 2006, 42, 623.	0.7	27
156	Liver iron measurement by MRI. Blood, 2005, 105, 437-438.	0.6	5
157	Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform. Analytical Biochemistry, 2005, 341, 241-250.	1.1	93
158	Left ventricular diastolic function compared with T2* cardiovascular magnetic resonance for early detection of myocardial iron overload in thalassemia major. Journal of Magnetic Resonance Imaging, 2005, 22, 229-233.	1.9	73
159	Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox).. Blood, 2005, 106, 3600-3600.	0.6	23
160	Hydroxyurea Treated Sickle Disorders Demonstrate Decreased Plasma Hb, Red Cell Vesicles and Thrombolysis.. Blood, 2005, 106, 2322-2322.	0.6	0
161	Normalized Left Ventricular Volumes and Function in Thalassemia Major Patients with Normal Myocardial Iron.. Blood, 2005, 106, 2707-2707.	0.6	1
162	Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. British Journal of Haematology, 2004, 127, 348-355.	1.2	340

#	ARTICLE	IF	CITATIONS
163	Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. <i>Blood</i> , 2004, 104, 263-269.	0.6	156
164	A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.. <i>Blood</i> , 2004, 104, 3193-3193.	0.6	17
165	Design, Synthesis, and Evaluation of Novel 2-Substituted 3-Hydroxypyridin-4-ones: A Structure-Activity Investigation of Metalloenzyme Inhibition by Iron Chelators. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 631-639.	2.9	67
166	Results of Long Term Iron Chelation Treatment with Deferoxamine. <i>Advances in Experimental Medicine and Biology</i> , 2002, 509, 91-125.	0.8	30
167	Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. , 2002, 15, 329-329.		42
168	Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2002, 15, 329-68.	0.7	24
169	Deferoxamine pharmacokinetics. <i>Seminars in Hematology</i> , 2001, 38, 63-68.	1.8	56
170	Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes. <i>Blood</i> , 2001, 98, 3831-3839.	0.6	49
171	Technical Report: Triple-Colour Staining Flow Cytometry for Co-Distribution of Thrombospondin Receptor (CD36), Ribonucleic Acid (RNA) and Fetal Haemoglobin (HbF) in Sickle Red Blood Cells. <i>Hematology</i> , 2001, 6, 91-100.	0.7	0
172	Practical management of iron overload. <i>British Journal of Haematology</i> , 2001, 115, 239-252.	1.2	317
173	Structure-Function Investigation of the Interaction of 1- and 2-Substituted 3-Hydroxypyridin-4-ones with 5-Lipoxygenase and Ribonucleotide Reductase. <i>Journal of Biological Chemistry</i> , 2001, 276, 48814-48822.	1.6	33
174	Deferoxamine pharmacokinetics. <i>Seminars in Hematology</i> , 2001, 38, 63-68.	1.8	26
175	Simplified flow cytometric method for fetal hemoglobin containing red blood cells. <i>Cytometry</i> , 2000, 42, 389-393.	1.8	31
176	Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β^2 -thalassemia. <i>Blood</i> , 2000, 95, 1229-1236.	0.6	259
177	The use of skin Fe levels as a surrogate marker for organ Fe levels, to monitor treatment in cases of iron overload. <i>Physics in Medicine and Biology</i> , 2000, 45, 1387-1396.	1.6	21
178	Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. <i>Journal of Hepatology</i> , 2000, 32, 727-733.	1.8	103
179	6-Alkoxyethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labelling with indium. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 1400-1406.	3.3	7
180	Quantification of Non-Transferrin-Bound Iron in the Presence of Unsaturated Transferrin. <i>Analytical Biochemistry</i> , 1999, 273, 212-220.	1.1	150

#	ARTICLE	IF	CITATIONS
181	Raised Neutrophil Phospholipase A2 Activity and Defective Priming of NADPH Oxidase and Phospholipase A2 in Sick Cell Disease. <i>Blood</i> , 1998, 91, 3423-3429.	0.6	31
182	Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. <i>Journal of Vascular Surgery</i> , 1997, 26, 265-273.	0.6	106
183	A Risk-Benefit Assessment of Iron-Chelation Therapy. <i>Drug Safety</i> , 1997, 17, 407-421.	1.4	85
184	The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 1997, 38, 114-122.	1.7	45
185	Cell cycle synchronisation by 3-hydroxypyridin-4-one iron chelators. <i>Cytotechnology</i> , 1996, 18, 127-133.	0.7	0
186	The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide Reductase. <i>Journal of Biological Chemistry</i> , 1996, 271, 20291-20299.	1.6	153
187	The Environment of the Lipoxygenase Iron Binding Site Explored with Novel Hydroxypyridinone Iron Chelators. <i>Journal of Biological Chemistry</i> , 1996, 271, 7965-7972.	1.6	62
188	Evaluation of New Iron Chelators for Clinical Use. <i>Acta Haematologica</i> , 1996, 95, 13-25.	0.7	35
189	The metabolites of nitric oxide in sickle-cell disease. <i>British Journal of Haematology</i> , 1995, 91, 834-837.	1.2	69
190	Iron Chelator Design. <i>Advances in Experimental Medicine and Biology</i> , 1994, 356, 343-349.	0.8	17
191	Lessons from Preclinical and Clinical Studies with 1,2-Diethyl-3-Hydroxypyridin-4-One, CP94 and Related Compounds. <i>Advances in Experimental Medicine and Biology</i> , 1994, 356, 361-370.	0.8	34
192	Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. <i>British Journal of Haematology</i> , 1993, 85, 393-400.	1.2	63
193	Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 2448-2458.	2.9	211
194	A direct method for quantification of non-transferrin-bound iron. <i>Analytical Biochemistry</i> , 1990, 186, 320-323.	1.1	136
195	Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: Choice of complexing agent and application to biological fluids. <i>Analytical Biochemistry</i> , 1990, 187, 212-219.	1.1	42
196	Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, iron(III)-chelating properties and biological activity. <i>Journal of Medicinal Chemistry</i> , 1990, 33, 1749-1755.	2.9	112
197	Facilitated uptake of zinc into human erythrocytes. <i>Biochemical Pharmacology</i> , 1990, 39, 1005-1012.	2.0	34
198	Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. <i>British Journal of Haematology</i> , 1989, 73, 403-409.	1.2	144

#	ARTICLE	IF	CITATIONS
199	Oral iron chelators: Prospects for future development. <i>European Journal of Haematology</i> , 1989, 43, 271-285.	1.1	31